Cargando…
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
BACKGROUND: Emerging evidence suggests that several factors can impact disease progression in transthyretin amyloid polyneuropathy (ATTR-PN). The present analysis used longitudinal data from Val30Met patients participating in the tafamidis (selective TTR stabilizer) clinical development program to e...
Autores principales: | Amass, Leslie, Li, Huihua, Gundapaneni, Balarama K., Schwartz, Jeffrey H., Keohane, Denis J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296038/ https://www.ncbi.nlm.nih.gov/pubmed/30558645 http://dx.doi.org/10.1186/s13023-018-0947-7 |
Ejemplares similares
-
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
por: Waddington Cruz, Márcia, et al.
Publicado: (2016) -
Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
por: Keohane, Denis, et al.
Publicado: (2015) -
Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015) -
Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy
por: Gundapaneni, B. K., et al.
Publicado: (2017) -
Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy
por: Sultan, Marla B, et al.
Publicado: (2017)